Search

Your search keyword '"van den Eertwegh, A J M"' showing total 457 results
Start Over Author "van den Eertwegh, A J M"
457 results on '"van den Eertwegh, A J M"'

1. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol

Author

Janssen, J. C., van Dijk, B., de Joode, K., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers-Sonderen, M. J., van den Eertwegh, A. J. M., de Groot, J. W. B., Jalving, M., de Jonge, M. J. A., Joosse, A., Kapiteijn, E., Kamphuis-Huismans, A. M., Naipal, K. A. T., Piersma, D., Rikhof, B., Westgeest, H. M., Vreugdenhil, G., Oomen-de Hoop, E., Mulder, E. E. A. P., and van der Veldt, Astrid A. M.

Published
2024
Full Text
View/download PDF

2. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma

Author

Leek, Lindsay V. M., Notohardjo, Jessica C. L., de Joode, Karlijn, Velker, Eline L., Haanen, John B. A. G., Suijkerbuijk, Karijn P. M., Aarts, Maureen J. B., de Groot, Jan Willem B., Kapiteijn, Ellen, van den Berkmortel, Franchette W. P. J., Westgeest, Hans M., de Gruijl, Tanja D., Retel, Valesca P., Cuppen, Edwin, van der Veldt, Astrid A. M., Labots, Mariette, Voest, Emile E., van de Haar, Joris, and van den Eertwegh, Alfons J. M.

Published
2024
Full Text
View/download PDF

3. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Author

Bührer, Emanuel, Kicinski, Michal, Mandala, Mario, Pe, Madeline, Long, Georgina V, Atkinson, Victoria, Blank, Christian U, Haydon, Andrew, Dalle, Stéphane, Khattak, Adnan, Carlino, Matteo S, Meshcheryakov, Andrey, Sandhu, Shahneen, Puig, Susana, Schadendorf, Dirk, Jamal, Rahima, Rutkowski, Piotr, van den Eertwegh, Alfonsus J M, Coens, Corneel, Grebennik, Dmitri, Krepler, Clemens, Robert, Caroline, and Eggermont, Alexander M M

Published
2024
Full Text
View/download PDF

4. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study

Author

van der Kooij, Monique K., Joosse, Arjen, Suijkerbuijk, Karijn P. M., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J. M., de Groot, Jan Willem B., Haanen, John B. A. G., Hospers, Geke A. P., Piersma, Djura, van Rijn, Rozemarijn S., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Westgeest, Hans M., Wouters, Michel W. J. M., Dekkers, Olaf M., and Kapiteijn, Ellen

Published
2023
Full Text
View/download PDF

6. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Author

Blankenstein, Stephanie A., Bonenkamp, Johannes J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Blokx, Willeke A. M., Boers-Sonderen, Marye J., van den Eertwegh, Alfons J. M., Franken, Margreet G., de Groot, Jan Willem B., Haanen, John B. A. G., Hospers, Geke A. P., Kapiteijn, Ellen W., van Not, Olivier J., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Westgeest, Hans M., Wouters, Michel W. J. M., and van Akkooi, Alexander C. J.

Published
2023
Full Text
View/download PDF

7. Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer

Author

Holleman, Marscha S., Huygens, Simone A., Al, Maiwenn J., Kuppen, Malou C. P., Westgeest, Hans M., van den Bergh, Alfonsus C. M., Bergman, Andries M., van den Eertwegh, Alfonsus J. M., Hendriks, Mathijs P., Lampe, Menuhin I., Mehra, Niven, van Moorselaar, Reindert J. A., van Oort, Inge M., Somford, Diederik M., de Wit, Ronald, van de Wouw, Agnes J., Gerritsen, Winald R., and Groot, Carin A. Uyl-de

Published
2022
Full Text
View/download PDF

8. Adjuvant treatment with anti‐PD‐1 in acral melanoma: A nationwide study.

Author

Bloem, Manja, van Not, Olivier J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Blokx, Willeke A. M., Boers‐Sonderen, Marye J., Bonenkamp, Johannes J., de Groot, Jan‐Willem B., Haanen, John B., Hospers, Geke A. P., Kapiteijn, Ellen W., de Meza, Melissa M., Piersma, Djura, van Rijn, Rozemarijn S., Stevense‐den Boer, Marion A. M., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, van den Eertwegh, Alfons J. M., and Suijkerbuijk, Karijn P. M.

Subjects
IMMUNE checkpoint inhibitors, IMMUNOLOGICAL adjuvants, OVERALL survival, REGRESSION analysis, MELANOMA
Abstract

Previous studies demonstrated limited efficacy of immune checkpoint inhibitors in unresectable acral melanoma (AM); it remains unclear how this translates to the adjuvant setting. This study investigates clinical outcomes of acral compared to cutaneous melanoma (CM) patients treated with adjuvant anti‐PD‐1 after complete resection. All stages III–IV AM and CM patients receiving adjuvant anti‐PD‐1 after complete resection between 2018 and 2022 were included from the prospective nationwide Dutch Melanoma Treatment Registry. We analyzed recurrence‐free survival (RFS), distant metastasis‐free survival (DMFS), and overall survival (OS). A multivariable Cox regression analysis of RFS was performed to adjust for potential confounders. We included 1958 (86 AM and 1872 CM) patients. At baseline, AM patients more frequently had KIT mutations, higher disease stages, and Eastern Cooperative Oncology Group Performance Status, and fewer BRAF and NRAS mutations. Median RFS was 14.8 months (95% confidence interval [CI]: 11.5–29.3) in AM and 37.4 months (95% CI: 34.6 to not reached) in CM (p =.002). After correcting for potential confounders, AM remained associated with a higher risk of recurrence (HRadj 1.53; 95% CI: 1.07–2.17; p =.019). Two‐year DMFS tended to be worse for AM than for CM: 64.5% versus 79.7% (p =.050). Two‐year OS was significantly lower in AM (71.5% vs. 84.3%; p =.027). The results of this study suggest a poorer outcome of adjuvant‐treated AM compared to CM. Studies assessing the added value of adjuvant treatment in AM are needed. Future research should investigate alternative treatment strategies to improve outcomes of high‐risk AM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Selective tumor antigen vaccine delivery to human CD169+ antigen-presenting cells using ganglioside-liposomes

Author

Affandi, Alsya J., Grabowska, Joanna, Olesek, Katarzyna, Venegas, Miguel Lopez, Barbaria, Arnaud, Rodríguez, Ernesto, Mulder, Patrick P. G., Pijffers, Helen J., Ambrosini, Martino, Kalay, Hakan, O’Toole, Tom, Zwart, Eline S., Kazemier, Geert, Nazmi, Kamran, Bikker, Floris J., Stöckl, Johannes, van den Eertwegh, Alfons J. M., de Gruijl, Tanja D., Storm, Gert, van Kooyk, Yvette, and den Haan, Joke M. M.

Published
2020

11. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy

Author

Verver, Danielle, Grünhagen, Dirk J., van Akkooi, Alexander C. J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., van den Eertwegh, Alfonsus J. M., de Groot, Jan Willem B., Boers-Sonderen, Marye J., Haanen, John B. A. G., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., Tije, Albert J.ten, Vreugdenhil, Gerard, Verhoef, Cornelis, and van der Veldt, Astrid A. M.

Published
2021
Full Text
View/download PDF

12. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Author

Blankenstein, Stephanie A., Bonenkamp, Johannes J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Blokx, Willeke A. M., Boers-Sonderen, Marye J., van den Eertwegh, Alfons J. M., Franken, Margreet G., de Groot, Jan Willem B., Haanen, John B. A. G., Hospers, Geke A. P., Kapiteijn, Ellen W., van Not, Olivier J., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Westgeest, Hans M., Wouters, Michel W. J. M., and van Akkooi, Alexander C. J.

Published
2023
Full Text
View/download PDF

14. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Author

Lesimple, Thierry, Maio, Michele, Linette, Gerald, Mortier, Laurent, Svane, Inge Marie, Schachter, Jacob, Brown, Michael, Hersey, Peter, Barrow, Catherine, Kudchadkar, Ragini, Dutriaux, Caroline, Song, Xinni, Quaglino, Pietro, Queirolo, Paola, Meier, Friedegund, Stroyakovskiy, Daniil, Guillot, Bernard, Romero, Pablo Luis Ortiz, Bastholt, Lars, Garbe, Claus, Grange, Florent, Mohr, Peter, Algazi, Alain, Bechter, Oliver, Hernberg, Micaela, Loquai, Carmen, Meiss, Frank, Chiarion Sileni, Vanna, Bar-Sela, Gil, Fitzharris, Bernard, Saiag, Philippe, Arnault, Jean-Philippe, Simon, Jan-Christoph, Stephens, Rosalie, Baurain, Jean-Francois, Lebbe, Célèste, Combemale, Patrick, Dummer, Reinhard, Hauschild, Axel, Parente, Phillip, Yamazaki, Naoya, Milhem, Mohammed, Leccia, Marie-Thérèse, Geoffrois, Lionel, Kretschmer, Lutz, Dunwoodie, Elaine, Walker, John, Lotem, Michal, Hendler, Daniel, Mackiewicz, Andrzej, Sekulovic, Lidija, Dzienis, Marcin, Hospers, Geke A.P., Siano, Marco, Hassel, Jessica, Corrie, Philippa, Passos, Maria-Jose, Levin, Max, Hoeller, Christoph, Machet, Laurent, Hallmeyer, Sigrun, Waterston, Ashita, Descamps, Vincent, Kiecker, Felix, Aarts, Maureen, Schmidt, Henrik, Raimundo, Ana, Nyakas, Marta, Lacour, Jean-Philippe, Berking, Carola, Ferrucci, Pier Francesco, Jameson, Michael, Kim, Kevin, Yokota, Kenji, Kerger, Joseph, Aubin, François, Groenewegen, Gerard, Kapiteijn, Helena, Boehncke, Wolf-Henning, Utikal, Jochen, Casasola, Richard, Marshall, Ernest, Ferraresi, Virginia, Richtig, Erika, Matkovic, Suzana, Inozume, Takashi, Crook, Timothy, McNeil, Catriona, Kiyohara, Yoshio, Avril, Marie-Francoise, Hein, Rüdiger, Terheyden, Patrick, Nathan, Paul, Aoi, Jun, Skytta, Tanja, Jouary, Thomas, Takenouchi, Tatsuya, Straume, Oddbjorn, Martins, César, Mukhametshina, Guzel, Bottomley, Andrew, Coens, Corneel, Mierzynska, Justyna, Blank, Christian U, Mandalà, Mario, Long, Georgina V, Atkinson, Victoria G, Dalle, Stéphane, Haydon, Andrew M, Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S, Sandhu, Shahneen, Puig, Susana, Ascierto, Paolo A, Larkin, James, Lorigan, Paul C, Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J M, Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C J, Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, Robert, Caroline, and Eggermont, Alexander M M

Published
2021
Full Text
View/download PDF

15. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Author

Menzies, Alex, Lesimple, Thierry, Maio, Michele, Linette, Gerald, Brown, Michael, Hersey, Peter, Svane, Inge Marie, Mortier, Laurent, Schachter, Jacob, Barrow, Catherine, Kudchadkar, Ragini, Song, Xinni, Dutriaux, Caroline, Quaglino, Pietro, Meier, Friedegund, Queirolo, Paola, Stroyakovskiy, Daniil, Bastholt, Lars, Guillot, Bernard, Garbe, Claus, Ortiz Romero, Pablo Luis, Grange, Florent, Mohr, Peter, Algazi, Alain, Bechter, Oliver, Hernberg, Micaela, Arnault, Jean-Philippe, Saiag, Philippe, Loquai, Carmen, Meiss, Frank, Simon, Jan-Christoph, Bar-Sela, Gil, Chiarion Sileni, Vanna, Fitzharris, Bernard, McCrystal, Mike, Parente, Phillip, Baurain, Jean-Francois, Combemale, Patrick, Lebbe, Célèste, Hauschild, Axel, Yamazaki, Naoya, Dummer, Reinhard, Milhem, Mohammed, Dzienis, Marcin, Walker, John, Geoffrois, Lionel, Leccia, Marie-Thérèse, Kretschmer, Lutz, Hendler, Daniel, Lotem, Michal, Mackiewicz, Andrzej, Sekulovic, Lidija, Dunwoodie, Elaine, Hoeller, Christoph, Machet, Laurent, Hassel, Jessica, Hospers, Geke A.P., Passos, Maria-Jose, Levin, Max, Fehr, Martin, Corrie, Philippa, Waterston, Ashita, Hallmeyer, Sigrun, Schmidt, Henrik, Descamps, Vincent, Lacour, Jean-Philippe, Berking, Carola, Kiecker, Felix, Ferrucci, Pier Francesco, Yokota, Kenji, Aarts, Maureen, Jameson, Michael, Winge-Main, Anna Katharina, Ferreira, Paula, Kim, Kevin, McNeil, Catriona, Hofmann-Wellenhof, Reiner, Kerger, Joseph, Aubin, François, Utikal, Jochen, Ferraresi, Virginia, Inozume, Takashi, Kiyohara, Yoshio, Groenewegen, Gerard, Kapiteijn, Helena, Matkovic, Suzana, Boehncke, Wolf-Henning, Casasola, Richard, Crook, Timothy, Marshall, Ernest, Skytta, Tanja, Avril, Marie-Francoise, Jouary, Thomas, Hein, Rüdiger, Terheyden, Patrick, Aoi, Jun, Takenouchi, Tatsuya, Straume, Oddbjorn, Martins, César, Mukhametshina, Guzel, Nathan, Paul, Eggermont, Alexander M M, Blank, Christian U, Mandalà, Mario, Long, Georgina V, Atkinson, Victoria G, Dalle, Stéphane, Haydon, Andrew M, Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S, Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A, Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J M, Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul C, van Akkooi, Alexander C J, Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, and Robert, Caroline

Published
2021
Full Text
View/download PDF

16. A prediction model for response to immune checkpoint inhibition in advanced melanoma

Author

van Duin, Isabella A. J., Verheijden, Rik J., van Diest, Paul J., Blokx, Willeke A. M., El-Sharouni, Mary-Ann, Verhoeff, Joost J. C., Leiner, Tim, van den Eertwegh, Alfonsus J. M., de Groot, Jan Willem B., van Not, Olivier J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Haanen, John B. A. G., Hospers, Geke A. P., Piersma, Djura, van Rijn, Rozemarijn S., van Der Veldt, Astrid A. M., Vreugdenhil, Gerard, Wouters, Michel W. J. M., Stevense-den Boer, Marion A. M., Boers-Sonderen, Marye J., Kapiteijn, Ellen, Suijkerbuijk, Karijn P. M., Elias, Sjoerd G., van Duin, Isabella A. J., Verheijden, Rik J., van Diest, Paul J., Blokx, Willeke A. M., El-Sharouni, Mary-Ann, Verhoeff, Joost J. C., Leiner, Tim, van den Eertwegh, Alfonsus J. M., de Groot, Jan Willem B., van Not, Olivier J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Haanen, John B. A. G., Hospers, Geke A. P., Piersma, Djura, van Rijn, Rozemarijn S., van Der Veldt, Astrid A. M., Vreugdenhil, Gerard, Wouters, Michel W. J. M., Stevense-den Boer, Marion A. M., Boers-Sonderen, Marye J., Kapiteijn, Ellen, Suijkerbuijk, Karijn P. M., and Elias, Sjoerd G.

Abstract

Predicting who will benefit from treatment with immune checkpoint inhibition (ICI) in patients with advanced melanoma is challenging. We developed a multivariable prediction model for response to ICI, using routinely available clinical data including primary melanoma characteristics. We used a population-based cohort of 3525 patients with advanced cutaneous melanoma treated with anti-PD-1-based therapy. Our prediction model for predicting response within 6 months after ICI initiation was internally validated with bootstrap resampling. Performance evaluation included calibration, discrimination and internal–external cross-validation. Included patients received anti-PD-1 monotherapy (n = 2366) or ipilimumab plus nivolumab (n = 1159) in any treatment line. The model included serum lactate dehydrogenase, World Health Organization performance score, type and line of ICI, disease stage and time to first distant recurrence—all at start of ICI—, and location and type of primary melanoma, the presence of satellites and/or in-transit metastases at primary diagnosis and sex. The over-optimism adjusted area under the receiver operating characteristic was 0.66 (95% CI: 0.64–0.66). The range of predicted response probabilities was 7%–81%. Based on these probabilities, patients were categorized into quartiles. Compared to the lowest response quartile, patients in the highest quartile had a significantly longer median progression-free survival (20.0 vs 2.8 months; P <.001) and median overall survival (62.0 vs 8.0 months; P <.001). Our prediction model, based on routinely available clinical variables and primary melanoma characteristics, predicts response to ICI in patients with advanced melanoma and discriminates well between treated patients with a very good and very poor prognosis.

Published
2024

17. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma

Author

MS Medische Oncologie, Cancer, Infection & Immunity, CMM Groep Van Mil, Leek, Lindsay V M, Notohardjo, Jessica C L, de Joode, Karlijn, Velker, Eline L, Haanen, John B A G, Suijkerbuijk, Karijn P M, Aarts, Maureen J B, de Groot, Jan Willem B, Kapiteijn, Ellen, van den Berkmortel, Franchette W P J, Westgeest, Hans M, de Gruijl, Tanja D, Retel, Valesca P, Cuppen, Edwin, van der Veldt, Astrid A M, Labots, Mariette, Voest, Emile E, van de Haar, Joris, van den Eertwegh, Alfons J M, MS Medische Oncologie, Cancer, Infection & Immunity, CMM Groep Van Mil, Leek, Lindsay V M, Notohardjo, Jessica C L, de Joode, Karlijn, Velker, Eline L, Haanen, John B A G, Suijkerbuijk, Karijn P M, Aarts, Maureen J B, de Groot, Jan Willem B, Kapiteijn, Ellen, van den Berkmortel, Franchette W P J, Westgeest, Hans M, de Gruijl, Tanja D, Retel, Valesca P, Cuppen, Edwin, van der Veldt, Astrid A M, Labots, Mariette, Voest, Emile E, van de Haar, Joris, and van den Eertwegh, Alfons J M

Published
2024

18. A prediction model for response to immune checkpoint inhibition in advanced melanoma

Author

Cancer, MS Medische Oncologie, Pathologie, Pathologie Pathologen staf, Pathologie Groep Van Diest, MS Radiotherapie, Brain, Circulatory Health, MS Radiologie, Infection & Immunity, Epi Kanker Team C, JC onderzoeksprogramma Kanker, van Duin, Isabella A J, Verheijden, Rik J, van Diest, Paul J, Blokx, Willeke A M, El-Sharouni, Mary-Ann, Verhoeff, Joost J C, Leiner, Tim, van den Eertwegh, Alfonsus J M, de Groot, Jan Willem B, van Not, Olivier J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Haanen, John B A G, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Stevense-den Boer, Marion A M, Boers-Sonderen, Marye J, Kapiteijn, Ellen, Suijkerbuijk, Karijn P M, Elias, Sjoerd G, Cancer, MS Medische Oncologie, Pathologie, Pathologie Pathologen staf, Pathologie Groep Van Diest, MS Radiotherapie, Brain, Circulatory Health, MS Radiologie, Infection & Immunity, Epi Kanker Team C, JC onderzoeksprogramma Kanker, van Duin, Isabella A J, Verheijden, Rik J, van Diest, Paul J, Blokx, Willeke A M, El-Sharouni, Mary-Ann, Verhoeff, Joost J C, Leiner, Tim, van den Eertwegh, Alfonsus J M, de Groot, Jan Willem B, van Not, Olivier J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Haanen, John B A G, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Stevense-den Boer, Marion A M, Boers-Sonderen, Marye J, Kapiteijn, Ellen, Suijkerbuijk, Karijn P M, and Elias, Sjoerd G

Published
2024

19. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?

Author

MS Medische Oncologie, Brain, Cancer, van der Hiel, Bernies, Aalbersberg, Else A, van den Eertwegh, Alfons J M, de Wit-van der Veen, Linda J, Stokkel, Marcel P M, Lopez-Yurda, Marta, Boellaard, Ronald, Kapiteijn, Ellen W, Hospers, Geke A P, Aarts, Maureen J B, de Vos, Filip Y F L, Boers-Sonderen, Marye J, van der Veldt, Astrid A M, de Groot, Jan Willem B, Haanen, John B A G, MS Medische Oncologie, Brain, Cancer, van der Hiel, Bernies, Aalbersberg, Else A, van den Eertwegh, Alfons J M, de Wit-van der Veen, Linda J, Stokkel, Marcel P M, Lopez-Yurda, Marta, Boellaard, Ronald, Kapiteijn, Ellen W, Hospers, Geke A P, Aarts, Maureen J B, de Vos, Filip Y F L, Boers-Sonderen, Marye J, van der Veldt, Astrid A M, de Groot, Jan Willem B, and Haanen, John B A G

Published
2024

20. Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort

Author

Cancer, MS Medische Oncologie, Infection & Immunity, Borgers, J S W, Burgers, F H, Schina, A, Van Not, O J, van den Eertwegh, A J M, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Boer, A M Stevense-den, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Wouters, M W J M, Suijkerbuijk, K P M, van Thienen, J V, Haanen, J B A G, Cancer, MS Medische Oncologie, Infection & Immunity, Borgers, J S W, Burgers, F H, Schina, A, Van Not, O J, van den Eertwegh, A J M, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Boer, A M Stevense-den, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Wouters, M W J M, Suijkerbuijk, K P M, van Thienen, J V, and Haanen, J B A G

Published
2024

21. BRAF/MEK inhibitor rechallenge in advanced melanoma patients

Author

Cancer, MS Medische Oncologie, Pathologie Pathologen staf, Infection & Immunity, Van Not, Olivier J, van den Eertwegh, Alfons J M, Haanen, John B, van Rijn, Rozemarijn S, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, de Groot, Jan Willem W B, Hospers, Geke AP, Kapiteijn, Ellen, Bloem, Manja, Piersma, Djura, Stevense-den Boer, Marion, Verheijden, Rik J, van der Veldt, Astrid A M, Wouters, Michel W J M, Blokx, Willeke A M, Suijkerbuijk, Karijn P M, Cancer, MS Medische Oncologie, Pathologie Pathologen staf, Infection & Immunity, Van Not, Olivier J, van den Eertwegh, Alfons J M, Haanen, John B, van Rijn, Rozemarijn S, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, de Groot, Jan Willem W B, Hospers, Geke AP, Kapiteijn, Ellen, Bloem, Manja, Piersma, Djura, Stevense-den Boer, Marion, Verheijden, Rik J, van der Veldt, Astrid A M, Wouters, Michel W J M, Blokx, Willeke A M, and Suijkerbuijk, Karijn P M

Published
2024

22. Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021

Author

Cancer, MS Medische Oncologie, Pathologie Pathologen staf, Infection & Immunity, van Not, Olivier J, van den Eertwegh, Alfons J M, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van Breeschoten, Jesper, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Ismail, Rawa K, Kapiteijn, Ellen, Bloem, Manja, De Meza, Melissa M, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion A M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Boers-Sonderen, Marye J, Blokx, Willeke A M, Wouters, Michel W J M, Suijkerbuijk, Karijn P M, Cancer, MS Medische Oncologie, Pathologie Pathologen staf, Infection & Immunity, van Not, Olivier J, van den Eertwegh, Alfons J M, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van Breeschoten, Jesper, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Ismail, Rawa K, Kapiteijn, Ellen, Bloem, Manja, De Meza, Melissa M, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion A M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Boers-Sonderen, Marye J, Blokx, Willeke A M, Wouters, Michel W J M, and Suijkerbuijk, Karijn P M

Published
2024

23. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Published
2021
Full Text
View/download PDF

24. Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.

Author

Gogas, Helen, Ravimohan, Shruthi, Datta, Antara, Chhibber, Aparna, Couselo, Eva Muñoz, Diab, Adi, Pereira, Caio, Quéreux, Gaëlle, Sandhu, Shahneen, Curti, Brendan, Khushalani, Nikhil I., Taylor, Matthew H., Daniels, Gregory A., Spreafico, Anna, Meniawy, Tarek, Van Den Eertwegh, Alfons J. M., Sun, Yongliang, Arriaga, Yull, Zhou, Ming, and Long, Georgina V.

Subjects
REGULATORY T cells, TUMOR markers, NIVOLUMAB, BIOMARKERS, T cells
Abstract

In PIVOT IO 001 (NCT03635983), the combination of the investigational interleukin-2 agonist bempegaldesleukin (BEMPEG) with nivolumab (NIVO) had no added clinical benefit over NIVO monotherapy in unresectable/metastatic melanoma. Pre-defined baseline and on-treatment changes in selected biomarkers were analyzed to explore the potential mechanisms underlying the clinical observations. In each treatment arm, higher baseline tumor mutational burden or immune infiltration/inflammation was associated with improved efficacy compared with lower levels. On-treatment peripheral biomarker changes showed that BEMPEG + NIVO increased all immune cell subset counts interrogated, including regulatory T cells. This was followed by attenuation of the increase in CD8 + T cells, conventional CD4 + T cells, and systemic interferon gamma levels at later treatment cycles in the combination arm. Changes in tumor biomarkers were comparable between arms. These biomarker results help provide a better understanding of the mechanism of action of BEMPEG + NIVO and may help contextualize the clinical observations from PIVOT IO 001. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. BRAF/MEK inhibitor rechallenge in advanced melanoma patients.

Author

Van Not, Olivier J., van den Eertwegh, Alfons J. M., Haanen, John B., van Rijn, Rozemarijn S., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Boers‐Sonderen, Marye J., de Groot, Jan Willem W. B., Hospers, Geke A. P., Kapiteijn, Ellen, Bloem, Manja, Piersma, Djura, Stevense‐den Boer, Marion, Verheijden, Rik J., van der Veldt, Astrid A. M., Wouters, Michel W. J. M., Blokx, Willeke A. M., and Suijkerbuijk, Karijn P. M.

Subjects
*IPILIMUMAB, *PROPORTIONAL hazards models, *BRAF genes, *MELANOMA, *LACTATE dehydrogenase
Abstract

Background: Effectivity of BRAF(/MEK) inhibitor rechallenge has been described in prior studies. However, structured data are largely lacking. Methods: Data from all advanced melanoma patients treated with BRAFi(/MEKi) rechallenge were retrieved from the Dutch Melanoma Treatment Registry. The authors analyzed objective response rate (ORR), progression‐free survival (PFS), and overall survival (OS) for both first treatment and rechallenge. They performed a multivariable logistic regression and a multivariable Cox proportional hazards model to assess factors associated with response and survival. Results: The authors included 468 patients in the largest cohort to date who underwent at least two treatment episodes of BRAFi(/MEKi). Following rechallenge, ORR was 43%, median PFS was 4.6 months (95% confidence interval [CI], 4.1–5.2), and median OS was 8.2 months (95% CI, 7.2–9.4). Median PFS after rechallenge for patients who discontinued first BRAFi(/MEKi) treatment due to progression was 3.1 months (95% CI, 2.7–4.0) versus 5.2 months (95% CI, 4.5–5.9) for patients who discontinued treatment for other reasons. Discontinuing first treatment due to progression and lactate dehydrogenase (LDH) levels greater than two times the upper limit of normal were associated with lower odds of response and worse PFS and OS. Symptomatic brain metastases were associated with worse survival, whereas a longer treatment interval between first treatment and rechallenge was associated with better survival. Responding to the first BRAFi(/MEKi) treatment was not associated with response or survival. Conclusions: This study confirms that patients benefit from rechallenge. Elevated LDH levels, symptomatic brain metastases, and discontinuing first BRAFi(/MEKi) treatment due to progression are associated with less benefit from rechallenge. A prolonged treatment interval is associated with more benefit from rechallenge. This study confirms that patients with advanced melanoma derive benefit from rechallenge with BRAFi(/MEKi). Elevated lactate dehydrogenase levels, symptomatic brain metastases, and discontinuing first BRAFi(/MEKi) treatment due to progression are associated with less benefit on rechallenge. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. A prediction model for response to immune checkpoint inhibition in advanced melanoma

Author

van Duin, Isabella A. J., primary, Verheijden, Rik J., additional, van Diest, Paul J., additional, Blokx, Willeke A. M., additional, El‐Sharouni, Mary‐Ann, additional, Verhoeff, Joost J. C., additional, Leiner, Tim, additional, van den Eertwegh, Alfonsus J. M., additional, de Groot, Jan Willem B., additional, van Not, Olivier J., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Blank, Christian U., additional, Haanen, John B. A. G., additional, Hospers, Geke A. P., additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Wouters, Michel W. J. M., additional, Stevense‐den Boer, Marion A. M., additional, Boers‐Sonderen, Marye J., additional, Kapiteijn, Ellen, additional, Suijkerbuijk, Karijn P. M., additional, and Elias, Sjoerd G., additional

Published
2024
Full Text
View/download PDF

27. Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial

Author

Mulder, E. E. A. P., de Joode, K., Litière, S., ten Tije, A. J., Suijkerbuijk, K. P. M., Boers-Sonderen, M. J., Hospers, G. A. P., de Groot, J. W. B., van den Eertwegh, A. J. M., Aarts, M. J. B., Piersma, D., van Rijn, R. S., Kapiteijn, E., Vreugdenhil, G., van den Berkmortel, F. W. P. J., Hoop, E. Oomen-de, Franken, M. G., Ryll, B., Rutkowski, P., Sleijfer, S., Haanen, J. B. A. G., and van der Veldt, A. A. M.

Published
2021
Full Text
View/download PDF

28. Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands

Author

van Zeijl, Michiel C T, van Breeschoten, Jesper, de Wreede, Liesbeth C, Wouters, Michel W J M, Hilarius, Doranne L, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Boers-Sonderen, Marye J, Suijkerbuijk, Karijn P M, Haanen, John B A G, van den Eertwegh, Alfons J M, Internal medicine, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, CCA - Cancer biology and immunology, Medical Oncology, and Radiology & Nuclear Medicine

Subjects
Pharmacology, Cancer Research, Ipilimumab plus nivolumab, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Immunology, real world, Brain Neoplasms/drug therapy, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], population-based, Nivolumab/therapeutic use, POOLED ANALYSIS, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Melanoma/pathology, SURVIVAL, Immunology and Allergy, Humans, METASTATIC MELANOMA, immunotherapy, Ipilimumab/therapeutic use, Netherlands
Abstract

Item does not contain fulltext In phase III trials, ipilimumab plus nivolumab combination therapy is highly efficacious for advanced melanoma, despite many treatment-related grades 3-4 adverse events. Here, we report real-world safety and survival outcomes of ipilimumab plus nivolumab for advanced melanoma. Patients with advanced melanoma who received first-line ipilimumab plus nivolumab between January 1, 2015 and June 30, 2021 were selected from the Dutch Melanoma Treatment Registry. We evaluated response status at 3, 6, 12, 18, and 24 months. OS and PFS were estimated with the Kaplan-Meier method. Separate analyses were performed for patients with or without brain metastases and for patients who met the inclusion criteria of the Checkmate-067 trial. In total, 709 patients received first-line ipilimumab plus nivolumab. Three hundred sixty (50.7%) patients experienced grade 3-4 adverse events, with 211 of the (58.6%) patients requiring hospital admission. The median treatment duration was 42 days (IQR = 31-139). At 24 months, disease control was achieved in 37% of patients. Median PFS since the start of treatment was 6.6 months (95% CI: 5.3-8.7), and median OS was 28.7 months (95% CI: 20.7-42.2). CheckMate-067 trial-like patients had a 4-year OS of 50% (95% CI: 43-59). Among patients with no asymptomatic or symptomatic brain metastases, the 4-year OS probabilities were 48% (95% CI: 41-55), 45% (95% CI: 35-57), and 32% (95% CI: 23-46). Ipilimumab plus nivolumab can achieve long-term survival in advanced melanoma patients in a real-world setting, including patients not represented in the CheckMate-067 trial. However, the proportion of patients with disease control in the real world is lower compared with clinical trials.

Published
2023

29. Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies

Author

Van Not, Olivier J, van den Eertwegh, Alfons J M, Haanen, John B, van Rijn, Rozemarijn S, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van Eijs, Mick J M, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, de Meza, Melissa, Piersma, Djura, Stevense-den Boer, Marion, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Medical Oncology, Erasmus MC other, Internal medicine, Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, CCA - Cancer biology and immunology, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Cancer Research, OUTCOMES, Survival, CANCERS, CHRONIC LYMPHOCYTIC-LEUKEMIA, Response, Haematologic malignancy, SOLID TUMORS, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Immune checkpoint inhibitors, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Oncology, CELLS, IMMUNOTHERAPY, Melanoma
Abstract

Background: Patients diagnosed with haematologic malignancies (HMs) have a higher risk of developing subsequent solid tumours, such as melanoma. Patients with HM were mostly excluded from clinical trials but potentially derive less benefit from immune checkpoint inhibitors (ICIs) due to disease-or treatment-related T-or B-cell dysfunction.Methods: All advanced melanoma patients treated with anti-PD-1-based treatment or tar-geted therapy between 2015 and 2021 were included from the prospective nationwide Dutch Melanoma Treatment Registry. Progression-free survival (PFS) and melanoma-specific sur-vival (MSS) were analysed for patients with HM (HM+) and without HM (HM-). A cox model was used to account for confounders associated with PFS and MSS.Results: In total, 4638 advanced melanoma patients received first-line anti-PD-1 mono -therapy (n = 1763), ipilimumab-nivolumab (n = 800), or BRAF(/MEK) inhibitors (n = 2075). Concurrent HMs were present for 46 anti-PD1-treated patients, 11 ipilimumab-nivolumab-treated patients and 43 BRAF(/MEK)-inhibitor-treated patients. In anti-PD-1-treated pa-tients, the median PFS was 2.8 months for HM+ and 9.9 months for HM- (p = 0.01). MSS was 41.2 months for HM+ and 58.1 months for HM- (p = 0.00086). In multivariable analysis, the presence of an HM was significantly associated with higher risk of melanoma progression (HRadj 1.62; 95% confidence interval [95% CI] 1.15-2.29; p = 0.006) and melanoma-related death (HRadj 1.74; 95% CI 1.09-2.78; p = 0.020). Median PFS and MSS for first-line BRAF (/MEK-) inhibitor-treated HM+ and HM- patients were not significantly different.Conclusions: Patients with HM and advanced melanoma show significantly worse melanoma -related outcomes when treated with ICI, but not targeted therapy, compared to patients without HM. Clinicians should be aware of potentially altered effectiveness of ICI in patients with active HM.(c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Published
2023

30. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Published
2022
Full Text
View/download PDF

31. Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort

Author

Borgers, J. S. W., primary, Burgers, F. H., additional, Schina, A., additional, Van Not, O. J., additional, van den Eertwegh, A. J. M., additional, Blank, C. U., additional, Aarts, M. J. B., additional, van den Berkmortel, F. W. P. J., additional, de Groot, J. W. B., additional, Hospers, G. A. P., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R. S., additional, Boer, A. M. Stevense‐den, additional, van der Veldt, A. A. M., additional, Vreugdenhil, G., additional, Boers‐Sonderen, M. J., additional, Wouters, M. W. J. M., additional, Suijkerbuijk, K. P. M., additional, van Thienen, J. V., additional, and Haanen, J. B. A. G., additional

Published
2023
Full Text
View/download PDF

33. A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

Author

van Not, Olivier J., primary, Wind, Thijs T., additional, Ismail, Rawa K., additional, Bhattacharya, Arkajyoti, additional, Jalving, Mathilde, additional, Blank, Christian U., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Boers-Sonderen, Marye J., additional, van den Eertwegh, Alfonsus J. M., additional, de Groot, Jan Willem B., additional, Haanen, John B., additional, Kapiteijn, Ellen, additional, Bloem, Manja, additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, Stevense-den Boer, Marion, additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Wouters, Michel W. J. M., additional, Blokx, Willeke A. M., additional, Suijkerbuijk, Karijn P. M., additional, Fehrmann, Rudolf S. N., additional, and Hospers, Geke A. P., additional

Published
2023
Full Text
View/download PDF

34. Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort.

Author

Borgers, J. S. W., Burgers, F. H., Schina, A., Van Not, O. J., van den Eertwegh, A. J. M., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Boer, A. M. Stevense‐den, van der Veldt, A. A. M., Vreugdenhil, G., Boers‐Sonderen, M. J., Wouters, M. W. J. M., Suijkerbuijk, K. P. M., and van Thienen, J. V.

Subjects
MELANOMA, SEASONS, OVERALL survival, COUNTRIES, SURVIVAL rate, ENVIRONMENTAL exposure, SEASONAL variations of diseases
Abstract

Despite the improved survival rates of patients with advanced stage melanoma since the introduction of ICIs, many patients do not have (long‐term) benefit from these treatments. There is evidence that the exposome, an accumulation of host‐extrinsic factors including environmental influences, could impact ICI response. Recently, a survival benefit was observed in patients with BRAF wild‐type melanoma living in Denmark who initiated immunotherapy in summer as compared to winter. As the Netherlands lies in close geographical proximity to Denmark and has comparable seasonal differences, a Dutch validation cohort was established using data from our nationwide melanoma registry. In this study, we did not observe a similar seasonal difference in overall survival and are therefore unable to confirm the Danish findings. Validation of either the Dutch or Danish findings in (combined) patient cohorts from other countries would be necessary to determine whether this host‐extrinsic factor influences the response to ICI‐treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Adjuvant treatment of in‐transit melanoma: Narrowing the knowledge gap left by clinical trials

Author

de Meza, Melissa M., primary, Blokx, Willeke A. M., additional, Bonenkamp, Han J., additional, Blank, Cristian U., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Boers‐Sonderen, Marye J., additional, de Groot, Jan Willem B., additional, Haanen, John B., additional, Hospers, Geke A. P., additional, Kapiteijn, Ellen W., additional, van Not, Olivier J., additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, Stevense‐Den Boer, Marion A., additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, van den Eertwegh, Alfons J. M., additional, Suijkerbuijk, Karijn P. M., additional, and Wouters, Michel W. J. M., additional

Published
2023
Full Text
View/download PDF

36. Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma

Author

van Duin, Isabella A. J., primary, Elias, Sjoerd G., additional, van den Eertwegh, Alfonsus J. M., additional, de Groot, Jan Willem B., additional, Blokx, Willeke A. M., additional, van Diest, Paul J., additional, Leiner, Tim, additional, Verhoeff, Joost J. C., additional, Verheijden, Rik J., additional, van Not, Olivier J., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Blank, Christian U., additional, Haanen, John B. A. G., additional, Hospers, Geke A. P., additional, Kamphuis, Anna M., additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Wouters, Michel W. J. M., additional, Stevense‐den Boer, Marion A. M., additional, Boers‐Sonderen, Marye J., additional, Kapiteijn, Ellen, additional, and Suijkerbuijk, Karijn P. M., additional

Published
2023
Full Text
View/download PDF

37. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., ten Tije, Bert-Jan J., van der Veldt, Astrid A. M., Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Published
2021
Full Text
View/download PDF

38. Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma

Author

van Duin, Isabella A J, Elias, Sjoerd G, van den Eertwegh, Alfonsus J M, de Groot, Jan Willem B, Blokx, Willeke A M, van Diest, Paul J, Leiner, Tim, Verhoeff, Joost J C, Verheijden, Rik J, van Not, Olivier J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Haanen, John B A G, Hospers, Geke A P, Kamphuis, Anna M, Piersma, Djura, van Rijn, Rozemarijn S, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Stevense-den Boer, Marion A M, Boers-Sonderen, Marye J, Kapiteijn, Ellen, Suijkerbuijk, Karijn P M, van Duin, Isabella A J, Elias, Sjoerd G, van den Eertwegh, Alfonsus J M, de Groot, Jan Willem B, Blokx, Willeke A M, van Diest, Paul J, Leiner, Tim, Verhoeff, Joost J C, Verheijden, Rik J, van Not, Olivier J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Haanen, John B A G, Hospers, Geke A P, Kamphuis, Anna M, Piersma, Djura, van Rijn, Rozemarijn S, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Stevense-den Boer, Marion A M, Boers-Sonderen, Marye J, Kapiteijn, Ellen, and Suijkerbuijk, Karijn P M

Abstract

Since the introduction of BRAF(/MEK) inhibition and immune checkpoint inhibition (ICI), the prognosis of advanced melanoma has greatly improved. Melanoma is known for its remarkably long time to first distant recurrence (TFDR), which can be decades in some patients and is partly attributed to immune-surveillance. We investigated the relationship between TFDR and patient outcomes after systemic treatment for advanced melanoma. We selected patients undergoing first-line systemic therapy for advanced melanoma from the nationwide Dutch Melanoma Treatment Registry. The association between TFDR and progression-free survival (PFS) and overall survival (OS) was assessed by Cox proportional hazard regression models. The TFDR was modeled categorically, linearly, and flexibly using restricted cubic splines. Patients received anti-PD-1-based treatment (n = 1844) or BRAF(/MEK) inhibition (n = 1618). For ICI-treated patients with a TFDR <2 years, median OS was 25.0 months, compared to 37.3 months for a TFDR >5 years (P = .014). Patients treated with BRAF(/MEK) inhibition with a longer TFDR also had a significantly longer median OS (8.6 months for TFDR <2 years compared to 11.1 months for >5 years, P = .004). The hazard of dying rapidly decreased with increasing TFDR until approximately 5 years (HR 0.87), after which the hazard of dying further decreased with increasing TFDR, but less strongly (HR 0.82 for a TFDR of 10 years and HR 0.79 for a TFDR of 15 years). Results were similar when stratifying for type of treatment. Advanced melanoma patients with longer TFDR have a prolonged PFS and OS, irrespective of being treated with first-line ICI or targeted therapy.

Published
2023

39. Adjuvant treatment of in-transit melanoma:Narrowing the knowledge gap left by clinical trials

Author

de Meza, Melissa M, Blokx, Willeke A M, Bonenkamp, Han J, Blank, Cristian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-Den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van den Eertwegh, Alfons J M, Suijkerbuijk, Karijn P M, Wouters, Michel W J M, de Meza, Melissa M, Blokx, Willeke A M, Bonenkamp, Han J, Blank, Cristian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-Den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van den Eertwegh, Alfons J M, Suijkerbuijk, Karijn P M, and Wouters, Michel W J M

Abstract

Few clinical trials address efficacy of adjuvant systemic treatment in patients with in-transit melanoma (ITM). This study describes adjuvant systemic therapy of ITM patients beyond clinical trials. In this study, we included stage III adjuvant-treated melanoma patients registered in the nationwide Dutch Melanoma Treatment Registry between July 2018 and December 2020. Patients were divided into three groups: nodal disease only, ITM only and ITM and nodal disease. Recurrence patterns, recurrence-free survival (RFS) and overall survival (OS) at 12-months were analyzed. In our study population of 1037 patients, 66.8% had nodal disease only, 16.7% had ITM only and 16.2% had ITM with nodal disease. RFS at 12-months was comparable in the nodal only and ITM only group (72.2% vs70.1%, P = .97) but lower in ITM and nodal disease patients (57.8%; P = .01, P < .01). Locoregional metastases occurred as first recurrence in 38.9% nodal disease only, 71.9% of ITM-only and 44.0% of ITM and nodal disease patients. Distant recurrences occurred in 42.3%, 18.8% and 36.0%, respectively (P = .02). 12-months OS was not significantly different for nodal disease only patients compared with ITM-only (94.4% vs 97.6%, P = .06) but was significantly higher for ITM-only compared with ITM and nodal disease patients (97.6% vs 91.0%, P < .01). In conclusion, we showed that in the adjuvant setting, RFS rates in ITM-only patients are similar to non-ITM, though better than in ITM and nodal disease patients. Adjuvant-treated ITM-only patients less often experience distant recurrences and have a superior OS compared with ITM and nodal disease patients.

Published
2023

40. Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma:A Propensity-Matched Outcome Analysis

Author

De Meza, Melissa M, Blokx, Willeke A M, Bonenkamp, Johannes J, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, De Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Van Not, Olivier J, Piersma, Djura, Van Rijn, Rozemarijn S, Stevense-den Boer, Marion, Van der Veldt, Astrid A M, Vreugdenhil, Gerard, Van den Eertwegh, Alfonsus J M, Suijkerbuijk, Karijn P M, Wouters, Michel W J M, De Meza, Melissa M, Blokx, Willeke A M, Bonenkamp, Johannes J, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, De Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Van Not, Olivier J, Piersma, Djura, Van Rijn, Rozemarijn S, Stevense-den Boer, Marion, Van der Veldt, Astrid A M, Vreugdenhil, Gerard, Van den Eertwegh, Alfonsus J M, Suijkerbuijk, Karijn P M, and Wouters, Michel W J M

Abstract

Adjuvant BRAF/MEK- and anti-PD-1 inhibition have significantly improved recurrence-free survival (RFS) compared to placebo in resected stage III BRAF-mutant melanoma. However, data beyond the clinical trial setting are limited. This study describes the toxicity and survival of patients treated with adjuvant BRAF/MEK inhibitors and compares outcomes to adjuvant anti-PD-1. For this study, stage III BRAF V600 mutant cutaneous melanoma patients treated with adjuvant BRAF/MEK-inhibition or anti-PD-1 were identified from the Dutch Melanoma Treatment Registry. BRAF/MEK- and anti-PD-1-treated patients were matched based on propensity scores, and RFS at 12 and 18 months were estimated. Between 1 July 2018 and 31 December 2021, 717 patients were identified. Of these, 114 patients with complete records were treated with BRAF/MEK therapy and 532 with anti-PD-1. Comorbidities (p = 0.04) and geographical region (p < 0.01) were associated with treatment choice. In 45.6% of BRAF/MEK-treated patients, treatment was prematurely discontinued. Grade ≥ 3 toxicity occurred in 11.5% of patients and was the most common cause of early discontinuation (71.1%). At 12 and 18 months, RFS in BRAF/MEK-treated patients was 85% and 70%, compared to 68% and 68% in matched anti-PD-1-treated patients (p = 0.03). In conclusion, comorbidities and geographical region determine the choice of adjuvant treatment in patients with resected stage III BRAF-mutant melanoma. With the currently limited follow-up, BRAF/MEK-treated patients have better RFS at 12 months than matched anti-PD-1-treated patients, but this difference is no longer observed at 18 months. Therefore, longer follow-up data are necessary to estimate long-term effectiveness.

Published
2023

41. Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands

Author

MS Medische Oncologie, Cancer, Infection & Immunity, van Zeijl, Michiel C T, van Breeschoten, Jesper, de Wreede, Liesbeth C, Wouters, Michel W J M, Hilarius, Doranne L, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Boers-Sonderen, Marye J, Suijkerbuijk, Karijn P M, Haanen, John B A G, van den Eertwegh, Alfons J M, MS Medische Oncologie, Cancer, Infection & Immunity, van Zeijl, Michiel C T, van Breeschoten, Jesper, de Wreede, Liesbeth C, Wouters, Michel W J M, Hilarius, Doranne L, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Boers-Sonderen, Marye J, Suijkerbuijk, Karijn P M, Haanen, John B A G, and van den Eertwegh, Alfons J M

Published
2023

42. A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

Author

Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, van Not, Olivier J, Wind, Thijs T, Ismail, Rawa K, Bhattacharya, Arkajyoti, Jalving, Mathilde, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, de Groot, Jan Willem B, Haanen, John B, Kapiteijn, Ellen, Bloem, Manja, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Blokx, Willeke A M, Suijkerbuijk, Karijn P M, Fehrmann, Rudolf S N, Hospers, Geke A P, Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, van Not, Olivier J, Wind, Thijs T, Ismail, Rawa K, Bhattacharya, Arkajyoti, Jalving, Mathilde, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, de Groot, Jan Willem B, Haanen, John B, Kapiteijn, Ellen, Bloem, Manja, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Blokx, Willeke A M, Suijkerbuijk, Karijn P M, Fehrmann, Rudolf S N, and Hospers, Geke A P

Published
2023

43. CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma

Author

Cancer, Beeldverwerking ISI, MS Medische Oncologie, Epi Kanker Team C, JC onderzoeksprogramma Kanker, MS Radiotherapie, Circulatory Health, Pathologie Pathologen staf, HEE, JC onderzoeksprogramma Methodologie, Pathologie, Medische Beeldanalyse, Researchgr. Systems Radiology, Infection & Immunity, Regenerative Medicine and Stem Cells, Ter Maat, Laurens S, van Duin, Isabella A J, Elias, Sjoerd G, Leiner, Tim, Verhoeff, Joost J C, Arntz, Eran R A N, Troenokarso, Max F, Blokx, Willeke A M, Isgum, Ivana, de Wit, Geraldine A, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, Boomsma, Martijn F, van den Eertwegh, Fons J M, de Groot, Jan Willem B, Piersma, Djura, Vreugdenhil, Art, Westgeest, Hans M, Kapiteijn, Ellen, van Diest, Paul J, Pluim, Josien P W, de Jong, Pim A, Suijkerbuijk, Karijn P M, Veta, Mitko, Cancer, Beeldverwerking ISI, MS Medische Oncologie, Epi Kanker Team C, JC onderzoeksprogramma Kanker, MS Radiotherapie, Circulatory Health, Pathologie Pathologen staf, HEE, JC onderzoeksprogramma Methodologie, Pathologie, Medische Beeldanalyse, Researchgr. Systems Radiology, Infection & Immunity, Regenerative Medicine and Stem Cells, Ter Maat, Laurens S, van Duin, Isabella A J, Elias, Sjoerd G, Leiner, Tim, Verhoeff, Joost J C, Arntz, Eran R A N, Troenokarso, Max F, Blokx, Willeke A M, Isgum, Ivana, de Wit, Geraldine A, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, Boomsma, Martijn F, van den Eertwegh, Fons J M, de Groot, Jan Willem B, Piersma, Djura, Vreugdenhil, Art, Westgeest, Hans M, Kapiteijn, Ellen, van Diest, Paul J, Pluim, Josien P W, de Jong, Pim A, Suijkerbuijk, Karijn P M, and Veta, Mitko

Published
2023

44. Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies

Author

MS Medische Oncologie, Cancer, Infection & Immunity, Pathologie Pathologen staf, Van Not, Olivier J, van den Eertwegh, Alfons J M, Haanen, John B, van Rijn, Rozemarijn S, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van Eijs, Mick J M, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, de Meza, Melissa, Piersma, Djura, Stevense-den Boer, Marion, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, MS Medische Oncologie, Cancer, Infection & Immunity, Pathologie Pathologen staf, Van Not, Olivier J, van den Eertwegh, Alfons J M, Haanen, John B, van Rijn, Rozemarijn S, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van Eijs, Mick J M, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, de Meza, Melissa, Piersma, Djura, Stevense-den Boer, Marion, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Suijkerbuijk, Karijn P M, and Blokx, Willeke A M

Published
2023

45. Adjuvant Treatment of In-Transit Melanoma: Narrowing the Knowledge Gap Left by Clinical Trials

Author

Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, de Meza, Melissa M, Blokx, Willeke A M, Bonenkamp, Han J, Blank, Cristian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van den Eertwegh, Alfons J M, Suijkerbuijk, Karijn P M, Wouters, Michel W J M, Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, de Meza, Melissa M, Blokx, Willeke A M, Bonenkamp, Han J, Blank, Cristian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van den Eertwegh, Alfons J M, Suijkerbuijk, Karijn P M, and Wouters, Michel W J M

Published
2023

46. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study

Author

MS Medische Oncologie, Cancer, Infection & Immunity, van der Kooij, Monique K, Joosse, Arjen, Suijkerbuijk, Karijn P M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Westgeest, Hans M, Wouters, Michel W J M, Dekkers, Olaf M, Kapiteijn, Ellen, MS Medische Oncologie, Cancer, Infection & Immunity, van der Kooij, Monique K, Joosse, Arjen, Suijkerbuijk, Karijn P M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Westgeest, Hans M, Wouters, Michel W J M, Dekkers, Olaf M, and Kapiteijn, Ellen

Published
2023

47. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Author

Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, Blankenstein, Stephanie A, Bonenkamp, Johannes J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Blokx, Willeke A M, Boers-Sonderen, Marye J, van den Eertwegh, Alfons J M, Franken, Margreet G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Westgeest, Hans M, Wouters, Michel W J M, van Akkooi, Alexander C J, Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, Blankenstein, Stephanie A, Bonenkamp, Johannes J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Blokx, Willeke A M, Boers-Sonderen, Marye J, van den Eertwegh, Alfons J M, Franken, Margreet G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Westgeest, Hans M, Wouters, Michel W J M, and van Akkooi, Alexander C J

Published
2023

48. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Author

Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, Blankenstein, Stephanie A, Bonenkamp, Johannes J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Blokx, Willeke A M, Boers-Sonderen, Marye J, van den Eertwegh, Alfons J M, Franken, Margreet G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Westgeest, Hans M, Wouters, Michel W J M, van Akkooi, Alexander C J, Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, Blankenstein, Stephanie A, Bonenkamp, Johannes J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Blokx, Willeke A M, Boers-Sonderen, Marye J, van den Eertwegh, Alfons J M, Franken, Margreet G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Westgeest, Hans M, Wouters, Michel W J M, and van Akkooi, Alexander C J

Published
2023

50. Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis

Author

De Meza, Melissa M., primary, Blokx, Willeke A. M., additional, Bonenkamp, Johannes J., additional, Blank, Christian U., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Boers-Sonderen, Marye J., additional, De Groot, Jan Willem B., additional, Haanen, John B. A. G., additional, Hospers, Geke A. P., additional, Kapiteijn, Ellen, additional, Van Not, Olivier J., additional, Piersma, Djura, additional, Van Rijn, Rozemarijn S., additional, Stevense-den Boer, Marion, additional, Van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Van den Eertwegh, Alfonsus J. M., additional, Suijkerbuijk, Karijn P. M., additional, and Wouters, Michel W. J. M., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results